Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

doi:10.4239/wjd.v15.i7.1518

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1678)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-5) series.

Item

Count

PDF

122

HTML

973

Figures (1-6)

140

Tables (1-5)

118

Sum=1353

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

174

Sum=233

Jul 15, 2024 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Jul 15, 2024; 15(7): 1518-1530
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1518

Table 5 Statistics on the incidence of adverse outcomes, n (%)

Groups	Cardiac death	Heart failure readmission	Total incidence
Control group (n = 51)	1 (1.96)	8 (15.68)	9 (17.64)
Study group (n = 51)	0	5 (9.80)	5 (9.80)
χ²	1.010	0.793	1.325
P value	0.315	0.373	0.250

Citation: Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety. World J Diabetes 2024; 15(7): 1518-1530
URL: https://www.wjgnet.com/1948-9358/full/v15/i7/1518.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i7.1518